CR20200643A - Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 - Google Patents
Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2Info
- Publication number
- CR20200643A CR20200643A CR20200643A CR20200643A CR20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A CR 20200643 A CR20200643 A CR 20200643A
- Authority
- CR
- Costa Rica
- Prior art keywords
- inhibitors
- cannabinoid receptor
- pyrazine compounds
- novel pyridine
- sup
- Prior art date
Links
- 102100036214 Cannabinoid receptor 2 Human genes 0.000 title abstract 2
- 101710187022 Cannabinoid receptor 2 Proteins 0.000 title abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003216 pyrazines Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
Abstract
La invención se refiere a un compuesto de fórmula (I) <img src="data:image/png;base64,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 (***)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18180137 | 2018-06-27 | ||
| PCT/EP2019/066811 WO2020002320A1 (en) | 2018-06-27 | 2019-06-25 | Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200643A true CR20200643A (es) | 2021-05-11 |
Family
ID=62814868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200643A CR20200643A (es) | 2018-06-27 | 2019-06-25 | Nuev0s compuestos de piridina y pirazina com0 inhibidores del receptor connabinoide 2 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12071420B2 (es) |
| EP (1) | EP3814329B1 (es) |
| JP (1) | JP7445610B2 (es) |
| CN (2) | CN112262132A (es) |
| AU (2) | AU2019294256B2 (es) |
| BR (1) | BR112020025013A2 (es) |
| CA (1) | CA3096777A1 (es) |
| CL (1) | CL2020003331A1 (es) |
| CO (1) | CO2020011855A2 (es) |
| CR (1) | CR20200643A (es) |
| IL (1) | IL279725B2 (es) |
| MA (1) | MA53002A (es) |
| MX (1) | MX2020012760A (es) |
| PE (1) | PE20210368A1 (es) |
| PH (1) | PH12020552152A1 (es) |
| SG (1) | SG11202009103WA (es) |
| WO (1) | WO2020002320A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018234284A1 (en) | 2017-06-20 | 2018-12-27 | F. Hoffmann-La Roche Ag | PYRIDINE DERIVATIVES |
| WO2020002270A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| JP2024541968A (ja) | 2021-10-28 | 2024-11-13 | ジェネンテック， インコーポレイテッド | 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7267094A (en) | 1993-07-28 | 1995-02-28 | Rhone-Poulenc Rorer Limited | Compounds as pde iv and tnf inhibitors |
| GB0222493D0 (en) * | 2002-09-27 | 2002-11-06 | Glaxo Group Ltd | Compounds |
| US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| DE602005009500D1 (de) * | 2004-02-24 | 2008-10-16 | Glaxo Group Ltd | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors |
| GB0418047D0 (en) | 2004-08-12 | 2004-09-15 | Syngenta Participations Ag | Fungicidal compositions |
| TWI316937B (en) | 2005-03-31 | 2009-11-11 | Schering Corp | Spirocyclic thrombin receptor antagonists |
| FR2887550A1 (fr) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | Derives de 1-benzylpyrazole-3-acetamide, leur preparation et leur application en therapeutique |
| CA2625189A1 (en) | 2005-10-19 | 2007-04-26 | Gruenenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| MX2009003316A (es) * | 2006-10-04 | 2009-04-09 | Hoffmann La Roche | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. |
| EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| RS54788B1 (sr) | 2011-08-25 | 2016-10-31 | Merck Sharp & Dohme | Inhibitori pirimidina pde10 |
| US9403808B2 (en) | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
| CN104903466B (zh) | 2012-11-05 | 2016-11-23 | 鲁比康基因组学公司 | 条形编码核酸 |
| CN104837818B (zh) | 2012-12-07 | 2017-07-14 | 霍夫曼-拉罗奇有限公司 | 可用作cb2激动剂的吡啶‑2‑酰胺 |
| RS56423B1 (sr) | 2012-12-07 | 2018-01-31 | Hoffmann La Roche | Piridin-2-amidi korisni kao cb2 agonisti |
| SI2928882T1 (sl) | 2012-12-07 | 2017-05-31 | F. Hoffmann-La Roche Ag | Pirazinski derivati kot agonisti receptorja CB2 |
| AU2013354278B2 (en) | 2012-12-07 | 2017-10-12 | F. Hoffmann-La Roche Ag | Novel pyridine derivatives |
| PL2978755T3 (pl) | 2013-03-26 | 2018-05-30 | Hoffmann La Roche | Nowe pochodne pirydyny |
| CN111170938A (zh) * | 2014-04-04 | 2020-05-19 | 豪夫迈·罗氏有限公司 | 作为大麻素受体激动剂的5,6-双取代的吡啶-2-甲酰胺 |
| WO2015150440A1 (en) * | 2014-04-04 | 2015-10-08 | F. Hoffmann-La Roche Ag | Pyridine-2-amides useful as cb2 agonists |
| CN106795121A (zh) | 2014-10-27 | 2017-05-31 | 豪夫迈·罗氏有限公司 | 放射性标记大麻素受体2配体 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| EP3386951B1 (en) | 2015-12-09 | 2020-02-26 | H. Hoffnabb-La Roche Ag | Phenyl derivatives as cannabinoid receptor 2 agonists |
| EP4134444B1 (en) | 2017-03-23 | 2024-10-02 | University of Washington | Methods for targeted nucleic acid sequence enrichment with applications to error corrected nucleic acid sequencing |
| TW201906818A (zh) | 2017-05-31 | 2019-02-16 | 美商５１１製藥公司 | 新穎氘取代之正子發射斷層掃描（ｐｅｔ）顯影劑及其藥理應用 |
| WO2018234284A1 (en) | 2017-06-20 | 2018-12-27 | F. Hoffmann-La Roche Ag | PYRIDINE DERIVATIVES |
| EA202092586A1 (ru) | 2018-05-15 | 2021-03-10 | Лундбекк Ла-Хойя Рисерч Сентер, Инк. | Ингибиторы magl |
| EP3995155A1 (en) | 2018-06-27 | 2022-05-11 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| WO2020002270A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists |
| MA53002A (fr) | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| EP3814328A1 (en) | 2018-06-27 | 2021-05-05 | F. Hoffmann-La Roche AG | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| TWI687701B (zh) | 2018-12-05 | 2020-03-11 | 宏碁股份有限公司 | 判斷電量狀態的方法及其電子裝置 |
-
2019
- 2019-06-25 MA MA053002A patent/MA53002A/fr unknown
- 2019-06-25 BR BR112020025013-9A patent/BR112020025013A2/pt unknown
- 2019-06-25 CR CR20200643A patent/CR20200643A/es unknown
- 2019-06-25 IL IL279725A patent/IL279725B2/en unknown
- 2019-06-25 AU AU2019294256A patent/AU2019294256B2/en active Active
- 2019-06-25 JP JP2020568525A patent/JP7445610B2/ja active Active
- 2019-06-25 WO PCT/EP2019/066811 patent/WO2020002320A1/en active Application Filing
- 2019-06-25 CA CA3096777A patent/CA3096777A1/en active Pending
- 2019-06-25 SG SG11202009103WA patent/SG11202009103WA/en unknown
- 2019-06-25 CN CN201980025482.7A patent/CN112262132A/zh active Pending
- 2019-06-25 EP EP19733484.0A patent/EP3814329B1/en active Active
- 2019-06-25 CN CN202411199620.2A patent/CN119161323A/zh active Pending
- 2019-06-25 PE PE2020001433A patent/PE20210368A1/es unknown
- 2019-06-25 MX MX2020012760A patent/MX2020012760A/es unknown
-
2020
- 2020-09-24 CO CONC2020/0011855A patent/CO2020011855A2/es unknown
- 2020-12-14 PH PH12020552152A patent/PH12020552152A1/en unknown
- 2020-12-17 US US17/125,650 patent/US12071420B2/en active Active
- 2020-12-21 CL CL2020003331A patent/CL2020003331A1/es unknown
-
2024
- 2024-07-26 US US18/785,279 patent/US20240383872A1/en active Pending
- 2024-09-12 AU AU2024219640A patent/AU2024219640A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020012760A (es) | 2021-03-25 |
| CN112262132A (zh) | 2021-01-22 |
| CA3096777A1 (en) | 2020-02-02 |
| CO2020011855A2 (es) | 2020-10-20 |
| JP7445610B2 (ja) | 2024-03-07 |
| PH12020552152A1 (en) | 2021-07-05 |
| IL279725B2 (en) | 2024-04-01 |
| US12071420B2 (en) | 2024-08-27 |
| SG11202009103WA (en) | 2020-10-29 |
| KR20210028202A (ko) | 2021-03-11 |
| EP3814329B1 (en) | 2024-01-17 |
| JP2021529157A (ja) | 2021-10-28 |
| CN119161323A (zh) | 2024-12-20 |
| MA53002A (fr) | 2021-05-05 |
| IL279725B1 (en) | 2023-12-01 |
| AU2019294256A1 (en) | 2020-09-24 |
| CL2020003331A1 (es) | 2021-05-07 |
| IL279725A (en) | 2021-03-01 |
| US20240383872A1 (en) | 2024-11-21 |
| BR112020025013A2 (pt) | 2021-03-23 |
| WO2020002320A1 (en) | 2020-01-02 |
| AU2019294256B2 (en) | 2024-06-20 |
| AU2024219640A1 (en) | 2024-10-03 |
| EP3814329C0 (en) | 2024-01-17 |
| PE20210368A1 (es) | 2021-02-26 |
| EP3814329A1 (en) | 2021-05-05 |
| US20210115011A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020012760A (es) | Nuevos compuestos de piridina y pirazina como inhibidores del receptor cannabinoide 2. | |
| MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
| MX2020009234A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos. | |
| PH12022551503A1 (en) | Kras mutant protein inhibitors | |
| MX384087B (es) | Piperidinas como inhibidores de menina. | |
| AU2018274723A1 (en) | Benzimidazolone derived inhibitors of BCL6 | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| MX383051B (es) | Compuestos que inhiben eif4a y métodos relacionados a los mismos. | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| GEP20207111B (en) | Heteroaryl compounds for kinase inhibition | |
| WO2018044767A3 (en) | Aminopyrimidines as alk inhibitors | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| NZ774355A (en) | Aminopyrimidine/pyrazine derivatives as ctps1 inhibitors | |
| MX2024013464A (es) | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos | |
| MX2021003843A (es) | Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer. | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| MX2016016528A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| JO3261B1 (ar) | مشتق بيريدين أحادي الحلقة | |
| MX2020013899A (es) | Derivados de pirazol como inhibidores de malt1. | |
| MX2020013699A (es) | Derivados de pirazol como inhibidores de malt1. | |
| NZ726638A (en) | Phosphatidylinositol 3-kinase inhibitors | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). |